Patents by Inventor Hsieng Sen Lu

Hsieng Sen Lu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sclerostin epitopes
    Patent number: 8003108
    Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.
    Type: Grant
    Filed: April 25, 2006
    Date of Patent: August 23, 2011
    Assignees: Amgen Inc., UCB SA
    Inventors: Hsieng Sen Lu, Christpher Paszty, Martyn Kim Robinson, Alistair James Henry, Kelly Sue Warmington, John Latham, Alastair Lawson, David Winkler, Aaron George Winters
  • Method for generating F(ab?)2 antibody fragments
    Patent number: 7794970
    Abstract: Methods for generating F(ab?)2 fragments from antibodies using thermolysin as well as F(ab?)2 fragments and compositions comprising F(ab?)2 fragments generated by the method are described.
    Type: Grant
    Filed: September 18, 2006
    Date of Patent: September 14, 2010
    Assignee: Amgen Inc.
    Inventors: John O. Hui, Mitsuru Haniu, Hsieng Sen Lu
  • Human CGRP Receptor Binding Proteins
    Publication number: 20100172895
    Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.
    Type: Application
    Filed: December 18, 2009
    Publication date: July 8, 2010
    Inventors: Thomas C. Boone, David W. Brankow, Colin V. Gegg, JR., Shaw-Fen Sylvia Hu, Chadwick T. King, Hsieng Sen Lu, Licheng Shi, Cen Xu
  • Antibodies to Dkk-1
    Patent number: 7709611
    Abstract: The present invention provides antibodies and immunologically functional fragments thereof that specifically bind Dkk-1 polypeptides. The subject antibodies and fragments bind with high affinity to a conformational epitope located in the carboxy region of the Dkk-1 protein. Methods for preparing such antibodies or fragments thereof as well as physiologically acceptable compositions containing the antibodies or fragments are also provided. Use of the antibodies and fragments to treat various diseases including bone disorders, inflammatory diseases, neurological diseases, ocular diseases, renal diseases, pulmonary diseases and skin diseases are also disclosed.
    Type: Grant
    Filed: August 4, 2005
    Date of Patent: May 4, 2010
    Assignee: Amgen Inc.
    Inventors: Ji Li, Wenyan Shen, Hsieng Sen Lu, William Gleason Richards
  • TREATMENT METHODS USING DKK-1 ANTIBODIES
    Publication number: 20100040619
    Abstract: The present invention provides antibodies and immunologically functional fragments thereof that specifically bind Dkk-1 polypeptides. The subject antibodies and fragments bind with high affinity to a conformational epitope located in the carboxy region of the Dkk-1 protein. Methods for preparing such antibodies or fragments thereof as well as physiologically acceptable compositions containing the antibodies or fragments are also provided. Use of the antibodies and fragments to treat various diseases including bone disorders, inflammatory diseases, neurological diseases, ocular diseases, renal diseases, pulmonary diseases and skin diseases are also disclosed.
    Type: Application
    Filed: October 21, 2009
    Publication date: February 18, 2010
    Applicant: AMGEN INC.
    Inventors: Ji LI, Wenyan SHEN, Hsieng Sen LU, William Gleason RICHARDS
  • BINDING AGENTS
    Publication number: 20090304713
    Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.
    Type: Application
    Filed: November 24, 2008
    Publication date: December 10, 2009
    Applicants: AMGEN INC., UCB PHARMA S.A.
    Inventors: Christoper Paszty, Martin Kim Robinson, Kevin Graham, Alistair James Henry, Kelly Sue Hoffmann, John Latham, Hsieng Sen Lu, Alastair Lawson, Andy Popplewell, Wenyan Shen, David G. Winkler, Aaron George Winters
  • Sclerostin-binding antibody
    Patent number: 7592429
    Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.
    Type: Grant
    Filed: April 25, 2006
    Date of Patent: September 22, 2009
    Assignees: UCB SA, Amgen Inc.
    Inventors: Christopher Paszty, Martyn Kim Robinson, Kevin Graham, Alistair James Henry, Kelly Sue Hoffmann, John Latham, Hsieng Sen Lu, Alastair Lawson, Andy Popplewell, Wenyan Shen, David Winkler, Aaron George Winters
  • Method for treating Schwann and colon cells in vitro
    Patent number: 5929032
    Abstract: The survival and proliferation of Schwann cells can be promoted by culturing such cells in the presence of peptides derived from the EGF-like domain of proteins from the NDF/heregulin family. Colon epithelial cells can be stimulated to multiply and differentiate by culturing such cells in the presence of the same peptides.
    Type: Grant
    Filed: December 5, 1996
    Date of Patent: July 27, 1999
    Assignee: Amgen Inc.
    Inventors: Josette Fran.cedilla.oise Carnahan, Shinichi Hara, Hsieng Sen Lu, John Philip Mayer, Steven Kiyoshi Yoshinaga
  • Method for the treatment of Schwann cells in vivo
    Patent number: 5849705
    Abstract: Schwann cells can be treated in vivo to survive longer and to proliferate by contacting them with peptides derived from the EGF-like domain of proteins of the NDF/heregulin family.
    Type: Grant
    Filed: December 5, 1996
    Date of Patent: December 15, 1998
    Assignee: Amgen Inc.
    Inventors: Josette Francoise Carnahan, Shinichi Hara, Hsieng Sen Lu, John Philip Mayer
  • Method for the treatment of colon epithelial cells in vivo
    Patent number: 5686415
    Abstract: Colon epithelial cells are stimulated to multiply, grow and mature by contacting them in vivo with peptides derived from the EGF-like domain of proteins of the NDF/heregulin family.
    Type: Grant
    Filed: December 5, 1996
    Date of Patent: November 11, 1997
    Assignee: Amgen Inc.
    Inventors: Josette Fran.cedilla.oise Carnahan, Shinichi Hara, Hsieng Sen Lu, John Philip Mayer, Steven Kiyoshi Yoshinaga
  • NDF peptides
    Patent number: 5670342
    Abstract: Novel peptides are described which are biologically active derivatives of the EGF-like domain of NDF/heregulins and which stimulate the proliferation and differentiation of colon epithelial cells and support the survival and growth of Schwann cells.
    Type: Grant
    Filed: April 6, 1995
    Date of Patent: September 23, 1997
    Assignee: Amgen Inc.
    Inventors: Josette Francoise Carnahan, Shinichi Hara, Hsieng Sen Lu, John Philip Mayer, Steven Kiyoshi Yoshinaga